Source: startupticker

NBE Therapeutics: SOTIO expands collaboration with NBE Therapeutics

In 2016 SOTIO and NBE Therapeutics have entered into a partnership. The two companies will now develop antibody-drug conjugate (ADC) for a second target. NBE is eligible for a fee, milestone payments, royalties as well as reimbursement of R&D expenses.

Read full article »

Top Competitors or Alternatives

Missing a competitor? Contribute!

Est. Annual Revenue
Est. Employees
Bertrand Damour's photo - CEO of NBE-Therapeutics

CEO

Bertrand Damour

CEO Approval Rating

90/100

NBE Therapeutics is a biotechnology company that develops and commercializes antibody-drug conjugates for the treatment of cancer. Read more